- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02121730
Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions (FRISC)
Identification of Key Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais, Normandy and Picardy Regions
Kidney transplantation is now the treatment of choice for end-stage renal disease (ESRD). Between 2800 and 3000 kidney transplants are performed each year in France and more than 33 000 patients are living with a functioning graft.
Preventing allograft rejection requires the use of immunosuppressive therapy, the intensity decreases as the distance from the day of transplantation. Unfortunately, treatment favors certain complications, including infectious and neoplastic. These represent a major cause of mortality in these patients. If the frequency of skin cancer is greatly increased in this population, that of solid tumors remains a concern. Approximately 20% of patients develop cancer after 10 years of graft , half non- skin cancers, the main risk factor is immunosuppressive therapy .
The aim of the study is to evaluate, in a large population of patients treated in 4 regions ( the Nord-Pas de Calais, the Upper and Lower Normandy and Picardy) risk factors (in particular the nature of the immunosuppressive treatment) of developing a neoplastic complication, skin cancers and solid tumors, after renal transplantation.
Visão geral do estudo
Status
Condições
Descrição detalhada
A retrospective analysis of the previous 10 years, from 2002 to 2011 will be conducted. This study will better understand the epidemiology of these complications but also allow to identify risk factors associated, including demographic, environmental and related to immunosuppressive therapy.
Thereafter, we hope to implement preventive measures or prospective studies, allowing us to reduce the prevalence of this complication.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Locais de estudo
-
-
-
Amiens, França, 80000
- Recrutamento
- CHU Amiens
-
Investigador principal:
- Gabriel Choukroun, MD, PhD
-
Caen, França, 14000
- Ainda não está recrutando
- CHU Caen
-
Contato:
- Bruno Hurault de Ligny, MD, PhD
- E-mail: huraultdeligny-b@chu-caen.fr
-
Investigador principal:
- Bruno Bruno Hurault de Ligny, MD, PhD
-
Lille, França, 59000
- Ainda não está recrutando
- CHRU Lille
-
Contato:
- Marc HAZZAN, MD, PhD
- E-mail: m-hazzan@chru-lille.fr
-
Investigador principal:
- Marc Hazzan, MD, PhD
-
Rouen, França, 76000
- Ainda não está recrutando
- CHU Rouen
-
Contato:
- Michel GODIN, MD, PhD
- E-mail: michel.godin@chu-rouen.fr
-
Investigador principal:
- Michel Godin, MD, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- All adult renal transplant patients in the 4 centers of interregion North - West
- Patients transplanted during the period from 1 January 2002 and 31 December 2011
- Patients recipients of first, second or third renal transplantation
- Patients transplant recipients from a living or deceased donor whatever the immunological risk
- Eligible patients will be included after being informed by their doctor and after accepting their data to be processed in the framework of this study
- Patient with a health insurance coverage
Exclusion Criteria:
- Patients transplanted as child
- Patients transplanted before 1 January 2002
- Patients followed in the interregion but transplanted in another center
- Patients recipients of a double transplant (two kidneys or kidney plus other organ)
- Patients that do not accept their medical data to be included in the database
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
---|
Kidney Transplantation
Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Association between neoplastic complications and cancers
Prazo: 10 years
|
Correlation, in a population of renal transplant patients followed in interregion Northwest, of the association of neoplastic complications after renal transplantation, skin cancers and solid tumors outside the non-Hodgkin's lymphoma and the terms of immunosuppressive treatment used
|
10 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Risk factors
Prazo: 10 years
|
Identify the main risk factors for developing cancer after transplantation, besides immunosuppressive therapy
|
10 years
|
Incidence
Prazo: 10 years
|
Evaluate the incidence of neoplastic complications after renal transplantation in interregion Northwest
|
10 years
|
Typology of cancers
Prazo: 10 years
|
Assess the distribution and respective frequency of different types of cancer, skin and solid tumors in this group of patients
|
10 years
|
Survival prognosis
Prazo: 10 years
|
Establish the prognosis and survival of transplanted patients with a diagnosis of cancer after transplantation
|
10 years
|
Survival factors
Prazo: 10 years
|
Analyze the factors associated with the survival of transplanted patients who developed cancer after transplantation
|
10 years
|
Graft survival
Prazo: 10 years
|
Evaluate graft survival in the group of patients who develop post- transplantation cancer , especially after cancer diagnosis
|
10 years
|
Rejection number
Prazo: 10 years
|
Determine the number of cellular acute rejection and humoral rejections in patients who developed cancer and those free from this complication and analyze the prevalence of releases in the period following the diagnosis of cancer
|
10 years
|
Renal function after cancer
Prazo: 10 years
|
To analyze the evolution of renal function after cancer diagnosis
|
10 years
|
Cancer management
Prazo: 10 years
|
Analyze the management of these cancers, in particular as regards the strategy of immunosuppressive therapy after cancer diagnosis
|
10 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Gabriel Choukroun, MD, PhD, CHU Amiens
- Cadeira de estudo: Marc Hazzan, MD, PhD, CHRU Lille
- Cadeira de estudo: Bruno Hurault de Ligny, MD, PhD, CHU Caen
- Cadeira de estudo: Michel Godin, MD, PhD, CHU Rouen
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PI2012_843_0006
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de rim
-
Aalborg UniversityConcluídoUltrassonografia Point of Care (POCUS)Dinamarca
-
Sorbonne UniversityAalborg UniversityRecrutamentoUltrassom Point of CareFrança
-
Asociacion Española Primera en SaludIntensive Care Unit Pasteur HospitalConcluídoUltrassom Point of CareUruguai
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaDesconhecidoUltrassom Point of CarePaquistão
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...ConcluídoTransgênero, HIV Continuum of CareEstados Unidos
-
Thomas Jefferson UniversityRecrutamentoVentilação mecânica | Ultrassom Point of Care | Oxigenação | Ventilação Manual | Distúrbio da função cardíaca pós-operatórioEstados Unidos
-
Hospital for Special Surgery, New YorkRecrutamentoPeptídeo 1 semelhante ao glucagon | Ultrassom Gástrico | Ultrassom Point of CareEstados Unidos, Canadá
-
Queens College, The City University of New YorkRecrutamentoPublicação de artigos submetidos ao American Journal of Public HealthEstados Unidos
-
Tanta UniversityDesconhecidoDiâmetro da bainha do nervo óptico | Ultrassom Point of CareEgito
-
Johann Wolfgang Goethe University HospitalConcluídoFormação de Coágulos e Agregação de Plaquetas em Testes Point of CareAlemanha